Ignite Creation Date:
2024-05-06 @ 3:35 AM
Last Modification Date:
2024-10-26 @ 11:35 AM
Study NCT ID:
NCT02320032
Status:
COMPLETED
Last Update Posted:
2018-08-29
First Post:
2014-12-16
Brief Title:
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Sponsor:
Alkermes Inc
Organization:
Alkermes Inc
Study Overview
Official Title:
A Phase 1 Randomized Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and pharmacokinetics PK of various doses and dosing intervals of aripiprazole lauroxil
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None